Alivus Life Sciences Ltd.

NSE: ALIVUS | BSE: 543322 | ISIN: INE03Q201024 | Industry: Pharmaceuticals
| Strong Performer, Getting Expensive
1419.7000 1.80 (0.13%)
NSE Sep 03, 2026 15:16 PM
Volume: 73,273
 

logo
Alivus Life Sciences Ltd.
27 Jan 2023
1419.70
0.13%
buy
by BOB Capital Markets Ltd.
Target: 585
BOB Capital Markets Ltd.
Q3 revenue up 6% QoQ to Rs 5.4bn supported by sequential recovery in API business to parent and PLI benefits
 
Alivus Life Sciences has gained 51.88% in the last 1 Year
More from Alivus Life Sciences Ltd.
Recommended
Market trades flat, analysts flag domestic growth concerns for Godrej Consumer Products
Trendlyne Marketwatch | 03 Sep 2026, 03:09PM
Five stocks to buy from analysts this week - September 1, 2026
The Baseline | 01 Sep 2026, 06:40PM
Glenmark Life Sciences: The hived off API business of Glenmark Pharma goes public
| 27 Jul 2021